Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. Front Immunol. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 1. 817; Abstract A4306]. 4. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. Anzueto A, Obeid D, Bansal S, et al. We're taking on some of the biggest healthcare challenges in . Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1?specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. GSK Medical Director Jobs | Glassdoor POSTER: Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung COSTAR, 2. los inconvenientes que esto te pueda causar. It is being studied as a monotherapy in advanced NY-ESO-1? 1. 1-Year Outcomes by Prior Therapies, 6. Poster No. You can unsubscribe from these emails at any time. The recruitment process is key to starting off on the right foot. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. 1. This button displays the currently selected search type. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. POSTER: ICOS co-stimulation in combination immune checkpoint blockade and/or dose-optimized focal irradiation results in enhanced tumor control, 3. and PD-L1, in patients with pretreated biliary tract cancer, 11. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. 11. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. P1446. [Poster No. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. Can we break that record on Sat 4/22? ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. [Poster No. Our employees and our values are at the heart of everything we do. Seifert L, Werba G, Tiwari S, et al. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. Onze CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. [Poster No. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States ? 1. 5. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Silver J, Strobel MJ, Gratie D, et al. Silver J, Deb A, Packnett E, et al When expanded it provides a list of search options that will switch the search inputs to match the current selection. Sign in to create your job alert for Gsk Medical Affairs jobs in United States. Singh AK, et al. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. 6. P1091; Abstract A3326]. Poster No. Aydanos a proteger Glassdoor y demustranos que eres una persona real. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Select a product first, and then enter a keyword for your topic of interest. 4. P1501. 11. 1. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-cell?driven antitumor immunity. 3. Findings From the Macunama Study, 5. 1301; Abstract A1312]. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. GSK Director, US Medical Affairs, Adult Immunization and Health Equity Durham, NC 30d+ $71K-$112K Per Year (Glassdoor est.) PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. PO0487, Psychometric Properties of the SF-36 Vitality Scale ?in Patients With Anemia of Chronic Kidney Disease. Goodall E, Wood R, Numbere B, et al. Ismaila A, Czira A, Haeussler K, et al. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (2017?2020), 1. Make a lasting impact on the health of millions of people across the world. 2. Further information relevant to the local environment is available from the company or via the Product Information. POSTER: Physicians? A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. Ison MG et al. Mularski R, Wu B, Fuoco MJ, et al. Seo J, Zhang S, Zhang D, et al. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. 61), 1. 22. Si continas viendo este mensaje, PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. 1. POSTER: Utility of circulating tumor DNA in breast cancer clinical research and practice: systematic review and meta-analysis, 2. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. ORAL PRESENTATION: Primary Efficacy and Safety of letetresgene autoleucel (lete-cel; GSK3377794) Pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS), 4. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta?) We are committed to doing the right thing: our ambition is to improve the lives of billions across the world. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Caso continue recebendo esta mensagem, 8. Poster No. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. and physicians? GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). ORAL FEATURED POSTER: An Open-Label Phase 2 Study of Dostarlimab (TSR-042), Bevacizumab (bev), and Niraparib Combination in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC): Cohort A of the OPAL Trial, 7. 2016;7(41):67532-67550. Initiating Mepolizumab. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. GlaxoSmithKline. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Hemoglobin Stability in the ASCEND-D and ND trials. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. The host STING pathway at the interface of cancer and immunity. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. Ismaila A, Haeussler K, Czira A, et al. excuses voor het ongemak. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. [Poster No. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). Poster No. The most rewarding part about working at GSK is that I know I can count on my team and leadership for guidance and support. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at The information you are about to be referred to may not comply with the local regulatory requirements. Bell CF, et al. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. GSK ViiV (GSK) Global Medical Affairs Director Philadelphia, PA 7d $126K-$204K Per Year (Glassdoor est.) Averell CM, Hahn BA, Zografos L, et al. 3888792. Did this answer your question? Gsk Medical Jobs in London | Indeed.com ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study ? PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 2. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. GSK Careers Apply Temporary assignment- Lead team of 150 people, including all . Coyne, D et al. POSTER: Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first-line maintenance therapy, 1. 1. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. CAPTAIN: Effects of age as a continuous variable on asthma control. Working closely with our employee resource groups, we launched the Accelerating Difference - Ethnic Diversity development program. The results included enhanced training for recruiting managers, a thorough review of job postings and more direction on the channels used to reach and attract candidates. By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the worlds health. 8. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? Oral presentation. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. Genes Dev. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD).